Cargando…
Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study
BACKGROUND: In Ontario, patients with breast cancer typically receive their diagnoses through the Ontario Breast Screening Program (OBSP) after an abnormal screen, through screening initiated by a primary care provider or other referring physician, or through follow-up of symptoms by patients’ prima...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Impact Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259434/ https://www.ncbi.nlm.nih.gov/pubmed/35383035 http://dx.doi.org/10.9778/cmajo.20210254 |
_version_ | 1784741780287127552 |
---|---|
author | Habbous, Steven Homenauth, Esha Barisic, Andriana Kandasamy, Sharmilaa Majpruz, Vicky Forster, Katharina Yurcan, Marta Chiarelli, Anna M. Groome, Patti Holloway, Claire M.B. Eisen, Andrea |
author_facet | Habbous, Steven Homenauth, Esha Barisic, Andriana Kandasamy, Sharmilaa Majpruz, Vicky Forster, Katharina Yurcan, Marta Chiarelli, Anna M. Groome, Patti Holloway, Claire M.B. Eisen, Andrea |
author_sort | Habbous, Steven |
collection | PubMed |
description | BACKGROUND: In Ontario, patients with breast cancer typically receive their diagnoses through the Ontario Breast Screening Program (OBSP) after an abnormal screen, through screening initiated by a primary care provider or other referring physician, or through follow-up of symptoms by patients’ primary care providers. We sought to explore the association of the route to diagnosis (screening within or outside the OBSP or via symptomatic presentation) with use of OBSP-affiliated breast assessment sites (O-BAS), wait times until diagnosis or treatment, health care use and overall survival for patients with breast cancer. METHODS: In this retrospective cohort study, we used the Ontario Cancer Registry to identify adults (aged 18–105 yr) who received a diagnosis of breast cancer from 2013 to 2017. We excluded patients if they were not Ontario residents or had missing age or sex, or who died before diagnosis. We used logistic regression to evaluate factors associated with categorical variables (whether patients were or were not referred to an OBAS, whether patients were screened or symptomatic) and Cox proportional hazards regression to identify factors associated with all-cause mortality. RESULTS: Of 51 460 patients with breast cancer, 42 598 (83%) received their diagnoses at an O-BAS. Patients whose cancer was first detected through the OBSP were more likely than symptomatic patients to be given a diagnosis at an O-BAS (adjusted odds ratio 1.68, 95% confidence interval [CI] 1.57 to 1.80). Patients screened by the OBSP were given their diagnoses 1 month earlier than symptomatic patients, but diagnosis at an O-BAS did not affect the time until either diagnosis or treatment. Patients referred to an O-BAS had significantly better overall survival than those who were not referred (adjusted hazard ratio 0.73, 95% CI 0.66 to 0.80). INTERPRETATION: Patients screened through the OBSP were given their diagnoses earlier than symptomatic patients and were more likely to be referred to an O-BAS, which was associated with better survival. Our findings suggest that individuals with signs and symptoms of breast cancer would benefit from similar referral processes, oversight and standards to those used by the OBSP. |
format | Online Article Text |
id | pubmed-9259434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | CMA Impact Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92594342022-07-10 Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study Habbous, Steven Homenauth, Esha Barisic, Andriana Kandasamy, Sharmilaa Majpruz, Vicky Forster, Katharina Yurcan, Marta Chiarelli, Anna M. Groome, Patti Holloway, Claire M.B. Eisen, Andrea CMAJ Open Research BACKGROUND: In Ontario, patients with breast cancer typically receive their diagnoses through the Ontario Breast Screening Program (OBSP) after an abnormal screen, through screening initiated by a primary care provider or other referring physician, or through follow-up of symptoms by patients’ primary care providers. We sought to explore the association of the route to diagnosis (screening within or outside the OBSP or via symptomatic presentation) with use of OBSP-affiliated breast assessment sites (O-BAS), wait times until diagnosis or treatment, health care use and overall survival for patients with breast cancer. METHODS: In this retrospective cohort study, we used the Ontario Cancer Registry to identify adults (aged 18–105 yr) who received a diagnosis of breast cancer from 2013 to 2017. We excluded patients if they were not Ontario residents or had missing age or sex, or who died before diagnosis. We used logistic regression to evaluate factors associated with categorical variables (whether patients were or were not referred to an OBAS, whether patients were screened or symptomatic) and Cox proportional hazards regression to identify factors associated with all-cause mortality. RESULTS: Of 51 460 patients with breast cancer, 42 598 (83%) received their diagnoses at an O-BAS. Patients whose cancer was first detected through the OBSP were more likely than symptomatic patients to be given a diagnosis at an O-BAS (adjusted odds ratio 1.68, 95% confidence interval [CI] 1.57 to 1.80). Patients screened by the OBSP were given their diagnoses 1 month earlier than symptomatic patients, but diagnosis at an O-BAS did not affect the time until either diagnosis or treatment. Patients referred to an O-BAS had significantly better overall survival than those who were not referred (adjusted hazard ratio 0.73, 95% CI 0.66 to 0.80). INTERPRETATION: Patients screened through the OBSP were given their diagnoses earlier than symptomatic patients and were more likely to be referred to an O-BAS, which was associated with better survival. Our findings suggest that individuals with signs and symptoms of breast cancer would benefit from similar referral processes, oversight and standards to those used by the OBSP. CMA Impact Inc. 2022-04-05 /pmc/articles/PMC9259434/ /pubmed/35383035 http://dx.doi.org/10.9778/cmajo.20210254 Text en © 2022 CMA Impact Inc. or its licensors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Research Habbous, Steven Homenauth, Esha Barisic, Andriana Kandasamy, Sharmilaa Majpruz, Vicky Forster, Katharina Yurcan, Marta Chiarelli, Anna M. Groome, Patti Holloway, Claire M.B. Eisen, Andrea Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study |
title | Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study |
title_full | Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study |
title_fullStr | Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study |
title_full_unstemmed | Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study |
title_short | Differences in breast cancer diagnosis by patient presentation in Ontario: a retrospective cohort study |
title_sort | differences in breast cancer diagnosis by patient presentation in ontario: a retrospective cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259434/ https://www.ncbi.nlm.nih.gov/pubmed/35383035 http://dx.doi.org/10.9778/cmajo.20210254 |
work_keys_str_mv | AT habboussteven differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy AT homenauthesha differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy AT barisicandriana differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy AT kandasamysharmilaa differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy AT majpruzvicky differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy AT forsterkatharina differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy AT yurcanmarta differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy AT chiarelliannam differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy AT groomepatti differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy AT hollowayclairemb differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy AT eisenandrea differencesinbreastcancerdiagnosisbypatientpresentationinontarioaretrospectivecohortstudy |